Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adapalene/benzoyl peroxide/clindamycin phosphate (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Bausch Health Companies; Ortho Dermatologics

    • Most Recent Events

    • 01 May 2023 Results of post-hoc analysis assessing efficacy of IDP-126 gel to vehicle and three dyad component gels (n=394) published in the Pediatric Dermatology.
    • 21 Oct 2019 Status changed from active, no longer recruiting to completed.
    • 07 Feb 2019 Planned End Date changed from 18 Dec 2018 to 28 Jun 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top